Learning whether to subtract beta-blockers: it's about time.

Abstract

Proposed framework for foundational and provisional secondary prevention therapy over time in low-risk post-MI patients. Foundational therapies should be considered in all patients without contraindications, while provisional therapies should be considered in selected patients with comorbidities or post-infarction complications. The horizontal time axis proposes duration of therapies and timeframes for pharmacotherapeutic re-assessment, and should be responsive to the temporal evolution of post-MI risk and events. ADP, adenosine diphosphate receptor inhibitors; ASA, acetylsalicylic acid; CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hypertension; RAAS, renin-angiotensin-aldosterone system; RCT, randomized controlled trials; TG, triglyceride. *Pending guideline recommendations.

• Authors: Sean van Diepen, Paul W Armstrong
• Journal: European heart journal (Eur Heart J) Vol. 42 Issue 9 Pg. 915-918 (03 01 2021) ISSN: 1522-9645 [Electronic] England
• PMID: 33428708 (Publication Type: Editorial, Comment)
• Copyright: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: [email protected].

Chemical References

• Angiotensin-Converting Enzyme Inhibitors

Topics

• Angiotensin-Converting Enzyme Inhibitors
• Cohort Studies
• Denmark
• Heart Failure
• Humans
• Hypertension (drug therapy)
• Myocardial Infarction (drug therapy)
• Renin-Angiotensin System
• Reperfusion